Login

I cannot remember my username

Our New Website Is Here!
As part of our merger with St. Paul Research, we’ve created a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through our analysts’ combined insight, expertise, and perspective. Go to my.stpaulresearch.com to access our new site.

Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Sell Alert! Take a 130% Profit From Our December Trade… and Biotech Updates

Ray Blanco
By Ray BlancoPosted June 12, 2015

We're now up near 130% from our original entry price. That means we can reduce risk in our position in this biotech company by selling half our shares and recouping our original investment and then some. We can let the rest ride in what I expect will become a very successful biotech company.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Login

Ray Blanco

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Related Posts

Amicus Reports Phase 2 Data for Pompe Disease

Ray Blanco
By Ray BlancoPosted January 4, 2013

Welcome to this year's first update. I hope you enjoyed the holiday season, and I hope you have a great 2013. I enjoyed a packed house for Christmas, as family came into town to celebrate. I ended up with lots of cleanup and leftovers in the aftermath, but it was well worth it. 2012 was a great year for the biotechnology and the pharmaceutical industry, in general. In the U.S., 2012 saw more new FDA approvals than any year since 1998. I hope 2013 sets a new record. There are at least 30 compounds already on the FDA's calendar for a decision this year, so the odds are good.

TOPICS | , , , ,

A Deadly Virus Shines a Spotlight on Our Portfolio

Ray Blanco
By Ray BlancoPosted August 8, 2014

With what's looking to be the worst ever Ebola outbreak, lots of people are scared. There's little danger here right now, but that's not the case in parts of Africa, where things are particularly bad in countries like Liberia. Officially, the death toll is up to several hundred individuals, but the real numbers are probably much higher because of incomplete reporting. There's little hope of getting much help, even at a hospital, so many people aren't going. Bodies are being dumped out of doors. New cases aren't being reported because family members fear they'll be quarantined and exposed to infection too. So there are a lot of deaths that aren't being counted. The situation sounds horrible. A couple of our portfolio recommendations saw their share prices lifted this week when their usually ignored infectious disease programs were spotlighted in the midst of the Ebola drama playing out.

TOPICS | , , , ,